Provided by Tiger Trade Technology Pte. Ltd.

Roivant Sciences Ltd.

34.71
-2.8700-7.64%
Volume:8.76M
Turnover:310.07M
Market Cap:25.07B
PE:-73.85
High:37.13
Open:37.01
Low:34.69
Close:37.58
52wk High:37.97
52wk Low:11.94
Shares:722.41M
Float Shares:581.00M
Volume Ratio:1.69
T/O Rate:1.51%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4700
EPS(LYR):-0.5400
ROE:-8.52%
ROA:-16.48%
PB:5.93
PE(LYR):-64.28

Loading ...

Roivant Sciences price target raised to $42 from $36 at Guggenheim

TIPRANKS
·
Aug 07

Roivant Sciences Ltd : TD Cowen Raises Target Price to $50 from $41

THOMSON REUTERS
·
Aug 07

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 07

Roivant Sciences Ltd Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Immunovant, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Stock Track | Roivant Sciences Plunges 5.55% in pre-market After Q1 Loss Widens, Misses Estimates

Stock Track
·
Aug 06

Roivant Sciences' Fiscal Q1 Net Loss Narrows, Revenue Declines

MT Newswires Live
·
Aug 06

Immunovant FY27 Q1 Net Loss Widens 27% to $153.2 Million; R&D Expenses Rise 40.9% to $142.6 Million

Reuters
·
Aug 06

Earnings Flash (ROIV) Roivant Posts Fiscal Q1 Net Loss $0.26 a Share, vs. FactSet Est of $0.33 Loss

MT Newswires Live
·
Aug 06

Roivant Sciences Q1 Adj. EPS $(0.34) Misses $(0.32) Estimate, Sales $1.442M Miss $2.057M Estimate

Benzinga Earnings
·
Aug 06

Roivant Unit Priovant Begins Phase 3 Beacon+ Trial of Brepocitinib in Cutaneous Sarcoidosis

Reuters
·
Aug 06

Roivant Q1 FY27 Net Loss Widens to $290.61 Million; Revenue Slips to $1.44 Million

Reuters
·
Aug 06

Roivant Sciences Q1 Adjusted Net Income USD -290.606 Million Vs. IBES Estimate USD -192.3 Million

Reuters
·
Aug 06

Roivant Sciences - Brepocitinib Nda Approval and Launch in Dermatomyositis Expected by End of September 2026

THOMSON REUTERS
·
Aug 06

Roivant Sciences price target raised to $35 from $31.50 at BofA

TIPRANKS
·
Jul 31

Earning Preview: Roivant Sciences Ltd. Q2 revenue is expected to decrease by 71.57%, and institutional views are cautious

Earnings Agent
·
Jul 31

Roivant President, Immunovant CEO Eric Venker Sells USD 6.99 Million in Common Shares

Reuters
·
Jul 30

Roivant Sciences Announces Annual General Meeting of Shareholders

Reuters
·
Jul 29

Immunovant Director Atul Pande Disposes of 1,500 Common Shares for $59,700

Reuters
·
Jul 25

Immunovant Updates Financial Calendar with First-quarter Results Release and Business Update Call

Reuters
·
Jul 24